Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AST-004 for acute sports-related concussion in AFL athletes
ACTRN12625000657426Phase 2Recruiting
- Sponsor
- Astrocyte Pharmaceuticals Inc.
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of AST-004 in concussion (mTBI) (3 arms), sponsored by Astrocyte Pharmaceuticals Inc. Primary endpoint: Safety of AST-004 intravenous infusion. Started May 2025; status: recruiting.
02
Drugs
AST-004
03
Conditions
concussion (mTBI)
Beyond the preview
Go deeper on ACTRN12625000657426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625000657426.